Literature DB >> 18723428

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.

Carolyn J Owen1, Cynthia L Toze, Anna Koochin, Donna L Forrest, Clayton A Smith, Jane M Stevens, Shannon C Jackson, Man-Chiu Poon, Gary D Sinclair, Brian Leber, Peter R E Johnson, Anthony Macheta, John A L Yin, Michael J Barnett, T Andrew Lister, Jude Fitzgibbon.   

Abstract

Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a predisposition to myelodysplasia (MDS) and/or acute myeloid leukemia (AML). The disorder, caused by inherited mutations in RUNX1, is uncommon with only 14 pedigrees reported. We screened 10 families with a history of more than one first degree relative with MDS/AML for inherited mutations in RUNX1. Germ- line RUNX1 mutations were identified in 5 pedigrees with a 3:2 predominance of N-terminal mutations. Several affected members had normal platelet counts or platelet function, features not previously reported in FPD/AML. The median incidence of MDS/AML among carriers of RUNX1 mutation was 35%. Individual treatments varied but included hematopoietic stem cell transplantation from siblings before recognition of the inherited leukemogenic mutation. Transplantation was associated with a high incidence of complications including early relapse, failure of engraftment, and posttransplantation lymphoproliferative disorder. Given the small size of modern families and the clinical heterogeneity of this syndrome, the diagnosis of FPD/AML could be easily overlooked and may be more prevalent than previously recognized. Therefore, it would appear prudent to screen young patients with MDS/AML for RUNX1 mutation, before consideration of sibling hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723428     DOI: 10.1182/blood-2008-05-156745

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation.

Authors:  Hui Huang; Andrew J Woo; Zachary Waldon; Yocheved Schindler; Tyler B Moran; Helen H Zhu; Gen-Sheng Feng; Hanno Steen; Alan B Cantor
Journal:  Genes Dev       Date:  2012-07-03       Impact factor: 11.361

3.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

4.  Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies.

Authors:  Tim Ripperger; Kiran Tawana; Christian Kratz; Brigitte Schlegelberger; Jude Fitzgibbon; Doris Steinemann
Journal:  Eur J Hum Genet       Date:  2016-01-27       Impact factor: 4.246

5.  Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Authors:  Csaba Bödör; Aline Renneville; Matthew Smith; Aurélie Charazac; Sameena Iqbal; Pascaline Etancelin; Jamie Cavenagh; Michael J Barnett; Karolina Kramarzová; Biju Krishnan; András Matolcsy; Claude Preudhomme; Jude Fitzgibbon; Carolyn Owen
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

6.  In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.

Authors:  Jason H Mendler; Kati Maharry; Heiko Becker; Ann-Kathrin Eisfeld; Leigha Senter; Krzysztof Mrózek; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Michael A Caligiuri; Rebecca B Klisovic; Joseph O Moore; Thomas H Carter; Guido Marcucci; Clara D Bloomfield
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

7.  Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency.

Authors:  Tim Ripperger; Marcel Tauscher; Detlef Haase; Frank Griesinger; Brigitte Schlegelberger; Doris Steinemann
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

Review 8.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 9.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

Review 10.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.